Recommendations for Pregnant Members of Dermatology Health Care Teams During the COVID-19 Pandemic

Jose W. Ricardo, MD; Shari R. Lipner, MD, PhD

PRACTICE POINTS

- Pregnant women are at an increased risk for severe illness due to COVID-19 compared with nonpregnant women; therefore, it is important to protect pregnant health care workers who are caring for patients during the current pandemic.
- Although currently available COVID-19 vaccines have not been tested in pregnant women, they should not be withheld from pregnant individuals.
- Pregnant attending physicians and residents in dermatology can continue to provide care through telemedicine; if they choose to, and if all recommended personal protective equipment (PPE) are available, they can continue to provide in-person care.
- Correct and comprehensive use of PPE by pregnant health care workers is paramount to minimizing exposure to SARS-CoV-2.

Risks to Pregnant HCWs

Worldwide, viral pneumonia is a leading cause of death during pregnancy, with higher mortality documented among pregnant patients during the 1918 influenza pandemic and the 2003 severe acute respiratory syndrome–associated coronavirus pandemic, and an increased rate of hospital admission documented among these patients compared to the general population during the 2009 H1N1 influenza pandemic.

Data from the Centers for Disease Control and Prevention (CDC) suggest that pregnant women with symptomatic COVID-19 (n = 30,415) are at increased risk for the following (compared to nonpregnant women with symptomatic COVID-19 [n = 431,410]):

- Admission to the intensive care unit (10.5 of every 1000 cases vs 3.9 of every 1000 cases; adjusted risk ratio [aRR] = 3.0; 95% CI, 2.6-3.4)
- Receipt of invasive ventilation (2.9 of every 1000 cases vs 1.1 of every 1000 cases; aRR = 2.9; 95% CI, 2.2-3.8)
- Receipt of extracorporeal membrane oxygenation (0.7 of every 1000 cases vs 0.3 of every 1000 cases; aRR = 2.4; 95% CI, 1.5-4.0)
- Death (1.5 of every 1000 cases vs 1.2 of every 1000 cases; aRR = 1.7; 95% CI, 1.2-2.4).

Although the absolute risk of severe COVID-19–related outcomes is low, the CDC includes pregnant women in its increased risk category for COVID-19. Furthermore, in a systematic review of 61 studies comprising 790 COVID-19–positive pregnant women and 548 newborns, the rates of cesarean delivery, premature birth, low birth weight, and adverse pregnancy events are increased.
(the latter comprising preterm birth, death or stillbirth, and early termination of pregnancy) were estimated to be 72%, 23%, 7%, and 27%, respectively. In a systematic review of 39 studies (case series and cohort studies), comprising 936 SARS-CoV-2–tested newborns of mothers with COVID-19, mother-to-fetus transmission of SARS-CoV-2 occurred during the third trimester in approximately 3.2% of infected mothers.

In pregnant women with COVID-19 who develop cytokine storm syndrome, a fetal inflammatory response syndrome can ensue, which has been shown to cause ventricular expansion and bleeding in animal models. In addition, underlying conditions, such as cardiovascular disease, diabetes mellitus, pre-existing lung disease, and obesity, which are well-established risks factors for severe COVID-19 in nonpregnant patients, can increase the severity of COVID-19 in pregnant women.

**Recommendations From ACOG for Pregnant HCWs**

The American College of Obstetricians and Gynecologists recommends that health care facilities consider limiting the exposure of pregnant HCWs to patients with confirmed or suspected COVID-19. They also recommend that pregnant women continue to work in patient-facing roles if they want to, if recommended personal protective equipment (PPE) is available for them to wear. The US Food and Drug Administration issued an Emergency Use Authorization for 2 messenger RNA COVID-19 vaccines. Although these vaccines have not been tested in pregnant women, ACOG recommends that COVID-19 vaccines not be withheld from pregnant women who fulfill the criteria for vaccination; pregnant women who decline vaccination should be supported in their decision. In dermatology, telemedicine is an effective alternative to face-to-face visits, reducing the risk of transmitting SARS-CoV-2 to physicians and patients.

Ideally, pregnant dermatology attending physicians and residents can continue to provide care through tele-dermatology. They also can continue to provide in-person care, if they choose to, however, higher-risk procedures should be avoided. In dermatology, that might include ablative laser procedures to the face, prolonged surgery, and early termination of pregnancy. Dermatologists are of particular concern regarding the risk for transmitting SARS-CoV-2 and should be avoided. Correct and universal use of PPE is paramount; when all recommended PPE are available, they may continue to work in patient-facing roles until they give birth if they desire to do so. Alternatively, telemedicine and non–face-to-face rotations should be encouraged. Higher-risk and aerosol-generating procedures are of particular concern regarding the risk for transmitting SARS-CoV-2 and should be avoided. Correct and universal use of PPE is paramount; when all recommended PPE is not available, pregnant HCWs should avoid exposure to patients with suspected or confirmed COVID-19. These recommendations will help safeguard pregnant members of dermatology teams during the COVID-19 pandemic while maximizing patient care.

**References**


**Final Thoughts**

COVID-19 has brought about acute and likely permanent changes to the US health care system. Dermatologists are integral members of that system and are essential to the treatment of patients with skin, hair, and nail disorders. Pregnant dermatologists and residents should refrain from patient-facing roles when feasible; however, when all recommended PPE are available, they may continue to work in patient-facing roles until they give birth if they desire to do so. Alternatively, teledermatology and non–face-to-face rotations should be encouraged. Higher-risk and aerosol-generating procedures are of particular concern regarding the risk for transmitting SARS-CoV-2 and should be avoided. Correct and universal use of PPE is paramount; when all recommended PPE is not available, pregnant HCWs should avoid exposure to patients with suspected or confirmed COVID-19. These recommendations will help safeguard pregnant members of dermatology teams during the COVID-19 pandemic while maximizing patient care.


